LOUISVILLE, Ken., April 1, 2019 /PRNewswire/ -- US WorldMeds has announced that Sloan Pharma, S.a.r.l., a subsidiary of US WorldMeds Holdings, LLC, has received approval from the U.S. Food and Drug ...
Zelnorm was a steady seller for Novartis before cardiovascular red flags led to the irritable bowel syndrome (IBS) med’s collapse. Now—more than a decade after its recall and with new owners—Zelnorm's ...
Alfasigma USA Inc., which has a commercial hub in Bedminster, announced on Monday it has acquired the brand Zelnorm (tegaserod), a prescription pharmaceutical treatment for irritable bowel syndrome ...
US WorldMeds announced that the Food and Drug Administration (FDA) has approved the reintroduction of Zelnorm (tegaserod) for the treatment of irritable bowel syndrome with constipation (IBS-C) in ...
Novartis suspends US marketing and sales of Zelnorm(R) in response to request from FDA Retrospective analysis of pooled clinical trial data shows numerical imbalance in cardiovascular events in ...
Zelnorm (tegaserod; Alfasigma) is available again for the treatment of irritable bowel syndrome with constipation (IBS-C) in adult women <65 years of age Zelnorm (tegaserod; Alfasigma) is available ...
The decision to remove Zelnorm from the market was strictly a business decision. Alfasigma announced the withdrawal of the New Drug Application (NDA) for Zelnorm ® (tegaserod). The Company will no ...
BEDMINSTER, N.J.--(BUSINESS WIRE)--Alfasigma USA, Inc. today announced that ZELNORM™ (tegaserod) is now available in the United States as a prescription pharmaceutical treatment for irritable bowel ...
BEDMINSTER, N.J., July 23, 2020 (GLOBE NEWSWIRE) -- Alfasigma USA, Inc. today announced a strategic deal with Indegene, Inc., a global life sciences and healthcare solutions provider, to co-promote ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results